On April 2, 2024 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California (Press release, Zai Laboratory, APR 2, 2024, View Source [SID1234641727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The global oncology programs to be showcased at AACR (Free AACR Whitepaper) 2024 include a Phase 1a/1b study of ZL-1310 (NCT06179069), a novel antibody-drug conjugate (ADC) within the Zai Lab pipeline that targets the Delta-like ligand 3 (DLL3), a validated therapeutic target for the treatment of small cell lung cancer (SCLC). ZL-1310 is designed with a novel linker-payload platform TMALIN which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies.

Also featured at AACR (Free AACR Whitepaper) 2024 will be Zai Lab’s Phase 1 study (NCT05859464) of ZL-1218, an anti-CCR8 antibody that blocks regulatory T cells (Treg) which suppress antitumor immunity in tumor tissue and is designed to deplete Treg cells selectively in tumors and minimally in other tissue.

"These ongoing global clinical studies underscore Zai Lab’s continued commitment to pursue both novel and validated cancer biology targets and advance innovative oncology therapies that can potentially reach patients around the world," said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab. "We are dedicated to advancing the pipeline through both drug discovery and partnerships to address therapeutic challenges and unmet patient needs. As we extend the impact of our R&D innovation on a global scale, we look forward to highlighting these programs from our differentiated oncology pipeline at AACR (Free AACR Whitepaper) 2024."

Details regarding the Zai Lab poster presentations at AACR (Free AACR Whitepaper) 2024 are as follows:

Title: Trial in Progress: A Phase 1a/1b, An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Presenter: Linda Liu, Ph.D., Senior Vice President, Biologics Discovery, Zai Lab
Session: PO.CTP01.02 – Phase I Clinical Trials in Progress 2, CT155 / 6
Date/Time: Monday, April 8, 2024, 1:30 PM – 5:00 PM PT
Location: San Diego Convention Center

Title: Trial in Progress: A Phase I, Open-label, Multicenter Study of ZL-1218, an anti-CCR8 IgG1, as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor
Presenter: Maria Tea, M.D., Senior Medical Director, Zai Lab
Session: PO.CTP01.02 – Phase I Clinical Trials in Progress 2, CT162 / 13
Date/Time: Monday, April 8, 2024, 1:30 PM – 5:00 PM PT
Location: San Diego Convention Center